BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) entered into a licensing agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe, according to a company statement.

Under the agreement, BioCryst will receive $70 million upfront and up to $275 million in future regulatory and sales milestone payments. The company will also receive tiered royalties on net sales ranging from 18% to 30%.

Navenibart is an investigational, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical trials for hereditary angioedema. BioCryst stated its Phase 3 program remains on track to support a U.S. regulatory filing by the end of 2027.

The agreement builds upon a prior arrangement between the companies for the sale of BioCryst's European ORLADEYO business to Neopharmed Gentili in 2025. Neopharmed Gentili operates the European commercial infrastructure originally built by BioCryst for ORLADEYO, a plasma kallikrein inhibitor for hereditary angioedema.

"This deal enables both companies to build upon the strong foundation of ORLADEYO and leverages Neopharmed Gentili's expertise in Europe," said Charlie Gayer, BioCryst's president and chief executive officer.

Alessandro Del Bono, chief executive officer of Neopharmed Gentili, stated the agreement "underscores our steadfast dedication to advancing therapeutic innovation in areas of significant unmet medical need."

The transaction allows BioCryst to maintain commercial focus in the U.S. market while Neopharmed Gentili handles European commercialization for both ORLADEYO and navenibart in their respective territories.